Todo DSpace

Listar por tema "risankizumab"

Mostrando ítems 1-2 de 2

    • Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry) 

      Zitouni J., Bursztejn A.-C., Belloni Fortina A., Beauchet A., Di Lernia V., Lesiak A., Thomas J., Topkarci Z., Murashkin N., Brzezinski P., Torres T., Chiriac A., Luca C., McPherson T., Akinde M., Maruani A., Epishev R., Vidaurri de la Cruz H., Luna P.C., Amy de la Bretêque M., Lasek A., Bourrat E., Bachelerie M., Mallet S., Steff M., Bellissen A., Neri I., Zafiriou E., van den Reek J.M.P.A., Sonkoly E., Mahil S.K., Smith C.H., Flohr C., Bachelez H., Mahé E., the Groupe de Recherche sur le Psoriasis (GrPso) of the Societe Francaise de Dermatologie, the Groupe de recherche de la Societe Francaise de Dermatologie Pediatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Societa Italiana di Dermatologia Pediatrica (S.I.Der.P.) (2022)
      Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are ...

    • Mini review: New treatments in psoriatic arthritis. Focus on the IL-23/17 Axis 

      Sakkas L.I., Zafiriou E., Bogdanos D.P. (2019)
      Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 ...